Drug Trial Radar · NCT06989840
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Jun 3, 2025
Primary completion
Jan 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- Sagimet Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be an open-label, 2-way crossover investigation to assess the effect of food on a single dose of TVB-3567 administered orally in healthy participants. Part C will be a randomized, double-blind, placebo-controlled investigation of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants. Part D will be an open-label investigation of two doses of TVB-3567 across two cohorts, to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants with moderate to severe acne.
Conditions
- Acne
Interventions
TVB-3567Drug
Orally administered capsule
PlaceboDrug
Orally administered capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A - Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Baseline to 7 to 8 days after dosing
- Part B - Plasma AUC0-t in fasted and fed conditionsTime frame: Baseline to Day 4
- Part B - Plasma AUC0-inf in fasted and fed conditionsTime frame: Baseline to Day 4
- Part B - Plasma Cmax in fasted and fed conditionsTime frame: Baseline to Day 4
- Part B - Incidence of adverse events (AEs) and serious adverse events (SAEs) under fasted and fed conditionsTime frame: Baseline to 7 to 8 days after dosing
- Part C - Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Baseline to 13 to 15 days after the last dose
- Part D - Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Baseline to 13 to 15 days after the last dose
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Celerion, Inc.
Tempe, Arizona · Completed
Emeritus Research
Botany, New South Wales, Australia · Recruiting
The Skin Hospital
Darlinghurst, New South Wales, Australia · Not yet recruiting
Emeritus Research
Camberwell, Victoria, Australia · Recruiting
Nucleus Network
Melbourne, Victoria, Australia · Completed
Fremantle Dermatology
Fremantle, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.